OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -48.79 Million CAD | -25.9% |
| 2022 | -38.75 Million CAD | 57.8% |
| 2021 | -91.82 Million CAD | 36.9% |
| 2020 | -145.51 Million CAD | -2751.9% |
| 2019 | 5.48 Million CAD | -84.93% |
| 2018 | 36.41 Million CAD | 426.11% |
| 2017 | -11.16 Million CAD | -996.47% |
| 2016 | 1.24 Million CAD | 207.48% |
| 2015 | -1.15 Million CAD | -1635.72% |
| 2014 | -66.77 Thousand CAD | 82.21% |
| 2013 | -375.24 Thousand CAD | -167.72% |
| 2012 | -140.16 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -15.92 Million CAD | 59.53% |
| 2024 Q2 | -24.37 Million CAD | -53.04% |
| 2024 Q3 | -18.89 Million CAD | 79.29% |
| 2023 Q3 | -219.63 Million CAD | -1925.61% |
| 2023 FY | -112.4 Million CAD | -190.06% |
| 2023 Q1 | 4.05 Million CAD | 164.46% |
| 2023 Q2 | -10.84 Million CAD | -367.2% |
| 2023 Q4 | -39.36 Million CAD | 82.08% |
| 2022 Q2 | -6.95 Million CAD | 49.36% |
| 2022 Q3 | -11.78 Million CAD | -69.55% |
| 2022 Q4 | -6.29 Million CAD | 46.58% |
| 2022 FY | -38.75 Million CAD | 57.8% |
| 2022 Q1 | -13.72 Million CAD | 37.96% |
| 2021 Q4 | -22.12 Million CAD | -81.09% |
| 2021 Q1 | -28.21 Million CAD | 33.35% |
| 2021 Q2 | -29.27 Million CAD | -3.75% |
| 2021 FY | -91.82 Million CAD | 36.9% |
| 2021 Q3 | -12.21 Million CAD | 58.27% |
| 2020 FY | -145.51 Million CAD | -2751.9% |
| 2020 Q1 | 154 Thousand CAD | 100.56% |
| 2020 Q2 | -4.02 Million CAD | -2714.29% |
| 2020 Q3 | -99.3 Million CAD | -2366.69% |
| 2020 Q4 | -42.32 Million CAD | 57.38% |
| 2019 FY | 5.48 Million CAD | -84.93% |
| 2019 Q2 | -1.76 Million CAD | -103.82% |
| 2019 Q4 | -27.7 Million CAD | -145.42% |
| 2019 Q3 | -11.28 Million CAD | -538.46% |
| 2019 Q1 | 46.24 Million CAD | 58.69% |
| 2018 Q3 | 6.49 Million CAD | 192.69% |
| 2018 Q4 | 29.14 Million CAD | 348.41% |
| 2018 FY | 36.41 Million CAD | 426.11% |
| 2018 Q2 | 2.22 Million CAD | 253.61% |
| 2018 Q1 | -1.44 Million CAD | 31.16% |
| 2017 FY | -11.16 Million CAD | -996.47% |
| 2017 Q4 | -2.09 Million CAD | 14.64% |
| 2017 Q1 | -719 Thousand CAD | -202.17% |
| 2017 Q2 | -5.88 Million CAD | -718.88% |
| 2017 Q3 | -2.46 Million CAD | 58.22% |
| 2016 Q4 | 703.73 Thousand CAD | 43.04% |
| 2016 FY | 1.24 Million CAD | 207.48% |
| 2016 Q3 | 491.97 Thousand CAD | 182.3% |
| 2016 Q2 | 174.27 Thousand CAD | 240.14% |
| 2016 Q1 | -124.35 Thousand CAD | -217.76% |
| 2015 Q2 | -606.36 Thousand CAD | 25.92% |
| 2015 Q1 | -818.53 Thousand CAD | -340.38% |
| 2015 FY | -1.15 Million CAD | -1635.72% |
| 2015 Q4 | 105.59 Thousand CAD | -33.11% |
| 2015 Q3 | 157.85 Thousand CAD | 126.03% |
| 2014 Q3 | -25.18 Thousand CAD | -60.49% |
| 2014 Q2 | -15.69 Thousand CAD | -18.71% |
| 2014 Q1 | -13.22 Thousand CAD | -4.32% |
| 2014 Q4 | -185.87 Thousand CAD | -638.03% |
| 2014 FY | -66.77 Thousand CAD | 82.21% |
| 2013 FY | -375.24 Thousand CAD | -167.72% |
| 2013 Q3 | -2962.00 CAD | 94.95% |
| 2013 Q1 | -252.8 Thousand CAD | -315.97% |
| 2013 Q4 | -12.67 Thousand CAD | -327.85% |
| 2013 Q2 | -58.7 Thousand CAD | 76.78% |
| 2012 Q2 | -81.03 Thousand CAD | -1168.18% |
| 2012 Q3 | -43.44 Thousand CAD | 46.39% |
| 2012 Q4 | -60.77 Thousand CAD | -39.9% |
| 2012 FY | -140.16 Thousand CAD | 0.0% |
| 2012 Q1 | -6390.00 CAD | 31.26% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | -9296.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Theratechnologies Inc. | -10.62 Million USD | -359.115% |
| Harrow Health, Inc. | 580 Thousand USD | 8512.096% |
| Dynavax Technologies Corporation | -37.02 Million USD | -31.766% |
| Biofrontera Inc. | -22.67 Million USD | -115.153% |
| Cronos Group Inc. | -81.37 Million USD | 40.043% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -937.868% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 123.341% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -24.614% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 486.243% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -685.567% |
| Radius Health, Inc. | -3.92 Million USD | -1143.061% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -1283.422% |
| DURECT Corporation | -36.88 Million USD | -32.28% |
| ProPhase Labs, Inc. | -21.61 Million USD | -125.744% |
| Safety Shot Inc | -12.18 Million USD | -300.44% |
| Phibro Animal Health Corporation | 53.31 Million USD | 191.513% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -1839.799% |
| Alvotech | -354.86 Million USD | 86.251% |
| Assertio Holdings, Inc. | -243.53 Million USD | 79.966% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -825.985% |
| Rockwell Medical, Inc. | -6.67 Million USD | -631.487% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -919.584% |
| Procaps Group S.A. | 52.32 Million USD | 193.246% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 69.388% |
| SCYNEXIS, Inc. | 72.66 Million USD | 167.14% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -828.629% |
| Viatris Inc. | 766.2 Million USD | 106.368% |
| OptiNose, Inc. | -22.74 Million USD | -114.481% |
| SIGA Technologies, Inc. | 83.62 Million USD | 158.347% |
| Tilray Brands, Inc. | -174.74 Million USD | 72.079% |
| PetIQ, Inc. | 60.01 Million USD | 181.297% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -919.584% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 119.446% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -1025.152% |
| Alimera Sciences, Inc. | -1.47 Million USD | -3216.802% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 129.222% |
| Silver Spike Investment Corp. | 7.34 Million USD | 764.706% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -728.021% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 489.542% |
| Journey Medical Corporation | -2.07 Million USD | -2253.601% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -258.294% |
| Alpha Teknova, Inc. | -35.56 Million USD | -37.194% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -212.878% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 622.882% |
| PainReform Ltd. | -9.58 Million USD | -409.079% |
| Cosmos Health Inc. | -21.83 Million USD | -123.488% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 64.606% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -472.453% |
| Embecta Corp. | 221.5 Million USD | 122.027% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -930.04% |
| Talphera, Inc. | -16.88 Million USD | -188.887% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 155.649% |
| Incannex Healthcare Limited | -30.04 Million USD | -62.412% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -143.342% |
| Shineco, Inc. | -17.06 Million USD | -185.893% |
| Procaps Group, S.A. | 38.97 Million USD | 225.19% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 203.873% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -223.071% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 113.38% |
| Alvotech | -354.86 Million USD | 86.251% |
| Hempacco Co., Inc. | -8.81 Million USD | -453.661% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 191.275% |
| Bright Green Corporation | -8.89 Million USD | -448.735% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 68.636% |
| Kamada Ltd. | 10.06 Million USD | 584.799% |
| Indivior PLC | -4 Million USD | -1119.754% |
| Evoke Pharma, Inc. | -7.43 Million USD | -556.586% |
| Flora Growth Corp. | -50.35 Million USD | 3.106% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -143.342% |
| Evolus, Inc. | -49.23 Million USD | 0.899% |
| HUTCHMED (China) Limited | 18.37 Million USD | 365.525% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 124.768% |
| Akanda Corp. | -10.05 Million USD | -385.408% |